Patents by Inventor Armelle Phalipon

Armelle Phalipon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF
    Publication number: 20240024489
    Abstract: The present invention provides zwitterionic oligosaccharides, in particular fragments of the surface polysaccharides from Shigella sonnei and Shigella sonnei conjugates comprising them.
    Type: Application
    Filed: November 22, 2021
    Publication date: January 25, 2024
    Inventors: Laurence MULARD, Debashis DHARA, Helene PFISTER, Julie PAOLETTI, Armelle PHALIPON, Catherine GUERREIRO-INVERNO
  • Glycoconjugates and their use as potential vaccines against infection by
    Patent number: 10376593
    Abstract: The present invention relates to a conjugate comprising an oligo- or polysaccharide selected from the group consisting of: (X)x-{BCDA}n-(Y)y (X)x-{CDAB}n-(Y)y (X)x-{DABC}n-(Y)y (X)x-{ABCD}n-(Y)y wherein A, B, C, D, X and Y, x, y and n are as defined in claim 1, said oligo- or polysaccharide being bound to a carrier.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: August 13, 2019
    Inventors: Laurence Mulard, Pierre Chassagne, Philippe Sansonetti, Armelle Phalipon, Francois Traincard, Farida Nato
  • Glycoconjugates and use thereof as vaccine against serotype 3a and X
    Patent number: 10087242
    Abstract: The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: October 2, 2018
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS DESCARTES
    Inventors: Laurence Mulard, Julien Boutet, Catherine Guerreiro, Farida Nato, Philippe Sansonetti, Armelle Phalipon
  • Glycoconjugates and their use as potential vaccines against infection by
    Patent number: 9446109
    Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: September 20, 2016
    Assignee: INSERM (Institut National De La Sante Et De La Recherche Medicale)
    Inventors: Armelle Phalipon, Farida Nato, Laurence Mulard, Philippe Sansonetti, Françoise Baleux, Frédéric Belot, Cyrille Grandjean
  • GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI
    Publication number: 20150290331
    Abstract: The present invention relates to a conjugate comprising an oligo- or polysaccharide selected from the group consisting of: (X)x-{BCDA}n-(Y)y (X)x-{CDAB}n-(Y)y (X)x-{DABC}n-(Y)y (X)x-{ABCD}n-(Y)y wherein A, B, C, D, X and Y, x, y and n are as defined in claim 1, said oligo- or polysaccharide being bound to a carrier.
    Type: Application
    Filed: October 29, 2013
    Publication date: October 15, 2015
    Inventors: Laurence Mulard, Pierre Chassagne, Philippe Sansonetti, Armelle Phalipon, Francois Traincard, Farida Nato
  • GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X
    Publication number: 20150050282
    Abstract: The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.
    Type: Application
    Filed: June 20, 2014
    Publication date: February 19, 2015
    Applicants: INSTITUT PASTEUR, Centre National De La Recherche Scientifique, Universite Paris Descartes
    Inventors: Laurence MULARD, Julien BOUTET, Catherine GUERREIRO, Farida NATO, Philippe SANSONETTI, Armelle PHALIPON
  • Glycoconjugates and use thereof as vaccine against serotype 3a and X
    Patent number: 8815239
    Abstract: The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: August 26, 2014
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique, Universite Paris Descartes
    Inventors: Laurence Mulard, Julien Boutet, Catherine Guerreiro, Farida Nato, Philippe Sansonetti, Armelle Phalipon
  • GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI
    Publication number: 20140161793
    Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
    Type: Application
    Filed: December 14, 2011
    Publication date: June 12, 2014
    Applicants: INSERM, INSTITUT PASTEUR, Centre National De La Recherche Scientifique
    Inventors: Armelle PHALIPON, Farida NATO, Laurence MULARD, Philippe SANSONETTI, Francoise BALEUX, Frederic BELOT, Cyrille GRANDJEAN
  • GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI
    Publication number: 20130243751
    Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
    Type: Application
    Filed: December 14, 2011
    Publication date: September 19, 2013
    Inventors: Armelle PHALIPON, Farida Nato, Laurence Mulard, Philippe Sansonetti, Françoise Baleux, Frédéric Belot, Cyrille Grandjean
  • Glycoconjugates and their use as potential vaccines against infection by
    Patent number: 8124380
    Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
    Type: Grant
    Filed: July 2, 2004
    Date of Patent: February 28, 2012
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Armelle Phalipon, Farida Nato, Laurence Mulard, Philippe Sansonetti, Françoise Baleux, Frédéric Belot, Cyrille Grandjean
  • Targeting the histone code as a bacterial strategy for selectively modulating gene expression
    Patent number: 8092989
    Abstract: The ospF gene of Shigella flexneri encodes a phosphatase, which is a member of a new class of phosphatases. The OspF phosphatase inhibits the activity of several proteins either by direct protein modification or transcription downregulation. These proteins include MAP kinase, IL-8, CCL20, IL-12, AP1, CREB, RPA p32, and BCL2 related proteins. Methods for treating diseases using OspF phosphatase, methods for identifying agents that modulate OspF phosphatase's activity, methods for identifying agents that mimic OspF phosphatase's activity, and immunogenic compositions comprising OspF phosphatase are provided. A strain of Shigella flexneri containing an inactivated ospF gene is also provided.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: January 10, 2012
    Assignees: Institut Pasteur, Inserm (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Laurence Arbibe, Philippe Sansonetti, Claude Parsot, Kim Dong Wook, Armelle Phalipon
  • Targeting the histone code as a bacterial strategy for selectively modulating gene expression
    Publication number: 20100322974
    Abstract: The ospF gene of Shigella flexneri encodes a phosphatase, which is a member of a new class of phosphatases. The OspF phosphatase inhibits the activity of several proteins either by direct protein modification or transcription downregulation. These proteins include MAP kinase, IL-8, CCL20, IL-12, AP1, CREB, RPA p32, and BCL2 related proteins. Methods for treating diseases using OspF phosphatase, methods for identifying agents that modulate OspF phosphatase's activity, methods for identifying agents that mimic OspF phosphatase's activity, and immunogenic compositions comprising OspF phosphatase are provided. A strain of Shigella flexneri containing an inactivated ospF gene is also provided.
    Type: Application
    Filed: December 22, 2008
    Publication date: December 23, 2010
    Inventors: Philippe Sansonetti, Laurence Arbibe, Claude Parsot, Dong Wook Kim, Armelle Phalipon
  • GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X
    Publication number: 20100239584
    Abstract: The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.
    Type: Application
    Filed: May 16, 2008
    Publication date: September 23, 2010
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS DESCARTES
    Inventors: Laurence Mulard, Julien Boutet, Catherine Guerreiro, Farida Nato, Philippe Sansonetti, Armelle Phalipon
  • Targeting the Histone Code as a Bacterial Strategy for Selectively Modulating Gene Expression
    Publication number: 20090324646
    Abstract: The ospF gene of Shigella flexneri encodes a phosphatase, which is a member of a new class of phosphatases. The OspF phosphatase inhibits the activity of several proteins either by direct protein modification or transcription downregulation. These proteins include MAP kinase, IL-8, CCL20, IL-12, AP1, CREB, RPA p32, and BCL2 related proteins. Methods for treating diseases using OspF phosphatase, methods for identifying agents that modulate OspF phosphatase's activity, methods for identifying agents that mimic OspF phosphatase's activity, and immunogenic compositions comprising OspF phosphatase are provided. A strain of Shigella flexneri containing an inactivated ospF gene is also provided.
    Type: Application
    Filed: September 15, 2006
    Publication date: December 31, 2009
    Inventors: Laurence Arbibe, Philippe Sansonetti, Claude France, Kim Dong Wook, Armelle Phalipon
  • Glycoconjugates and Their Use as Potential Vaccines Against Infection by Shigella Flexneri
    Publication number: 20080112951
    Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
    Type: Application
    Filed: July 2, 2004
    Publication date: May 15, 2008
    Inventors: Armelle Phalipon, Farida Nato, Laurence Mulard, Philippe Sansonetti, Francoise Baleux, Frederic Belot, Cyrille Grandjean
  • Targeting the histone code as a bacterial strategy for selectively modulating gene expression
    Publication number: 20070077254
    Abstract: The ospF gene of Shigella flexneri encodes a phosphatase, which is a member of a new class of phosphatases. The OspF phosphatase inhibits the activity of several proteins either by direct protein modification or transcription downregulation. These proteins include MAP kinase, IL-8, CCL20, IL-12, AP1, CREB, RPA p32, and BCL2 related proteins. Methods for treating diseases using OspF phosphatase, methods for identifying agents that modulate OspF phosphatase's activity, methods for identifying agents that mimic OspF phosphatase's activity, and immunogenic compositions comprising OspF phosphatase are provided. A strain of Shigella flexneri containing an inactivated ospF gene is also provided.
    Type: Application
    Filed: September 15, 2006
    Publication date: April 5, 2007
    Inventors: Philippe Sansonetti, Laurence Arbibe, Claude Parsot, Dong Kim, Armelle Phalipon
  • Methods for selecting immunogenic polypeptides
    Publication number: 20030124143
    Abstract: A purified immunogenic polypeptide comprises an epitope unit recognized by a protective monoclonal antibody having a high affinity and a high specificity for a surface polysaccharide of a pathogenic microorganism of bacterial, viral, or fungal origin. The polypeptide is capable of inducing an immune response in vivo against the pathogenic microorganism. The immune response confers protection in mice against challenge with the virulent microorganisms.
    Type: Application
    Filed: November 22, 2002
    Publication date: July 3, 2003
    Inventors: Armelle Phalipon, Philippe Sansonetti, Franco Felici, Riccardo Cortese, Jean Pierre Kraehenbuhl
  • Immunogenic polypeptides that mimic a surface polysaccharide antigen of a pathogenic microorganism, method for obtaining the same, and their use in vaccine compositions
    Patent number: 6528061
    Abstract: A purified immunogenic polypeptide comprises an epitope unit recognized by a protective monoclonal antibody having a high affinity and a high specificity for a surface polysaccharide of a pathogenic microorganism of bacterial, viral, or fungal origin. The polypeptide is capable of inducing an immune response in vivo against the pathogenic microorganism. The immune response confers protection in mice against challenge with the virulent microorganisms.
    Type: Grant
    Filed: August 31, 1998
    Date of Patent: March 4, 2003
    Inventors: Armelle Phalipon, Philippe Sansonetti, Franco Felici, Riccardo Cortese, Jean Pierre Kraehenbuhl